Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지

Adverse Drug Reaction Surveillance System in Korea

우리나라 약물유해반응 감시체계

  • Choi, Nam-Kyong (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Park, Byung-Joo (Department of Preventive Medicine, Seoul National University College of Medicine)
  • 최남경 (서울대학교 의과대학 예방의학교실) ;
  • 박병주 (서울대학교 의과대학 예방의학교실)
  • Published : 2007.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Despite extensive researches and pre-market clinical trials, only limited information on the adverse drug reactions (ADRs) of a drug can be collected at the time of market approval from regulatory agency. ADRs constitute a major public health problem. Post-marketing surveillance of drugs is important to detect signals for ADR. In Korea, one of the main methods for monitoring the safety of marketed drugs is spontaneous reporting system of suspected ADRs. Re-examination and re-evaluation system are in force for monitoring safety of new market approval drugs and currently under marketing drugs, respectively. Recently, regional pharmacovigilance centers were designated from Korean Food and Drug Administration for facilitating ADR surveillance. Over recent years, with the development of information technology, there has been an increased interest in establishing data mining system for detecting signals from Health Insurance Review Agency database. The purpose of this paper is to review the current status of Korean ADR surveillance system and suggest the possible solutions for developing active pharmacovigilance system in Korea.

Keywords

References

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-1205 https://doi.org/10.1001/jama.279.15.1200
  2. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001; 10(2): 113-119 https://doi.org/10.1002/pds.568
  3. Korea Food and Drug Administration (KFDA). Provision of Safety Information Management Regulation of Drugs. KFDA Notice No. 2004-30; 2004 (Korean)
  4. Park BJ. Activation of drug adverse event spontaneous reporting. J Korean Med Assoc 2002; 45(11): 1274-1279 (Korean)
  5. Park BJ. Re-examination system for new drugs in Korea. J Korean Soc Clin Pharmacol 1998; 6(1): 3-15 (Korean)
  6. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: Current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5(6): 363-375 https://doi.org/10.1002/(SICI)1099-1557(199611)5:6<363::AID-PDS249>3.0.CO;2-7
  7. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12(1): 17-29 https://doi.org/10.1002/pds.773
  8. Hauben M, Patadia V, Gerrits C, Walsh L, Reich L. Data mining in pharmacovigilance: The need for a balanced perspective. Drug Saf 2005; 28(10): 835-842 https://doi.org/10.2165/00002018-200528100-00001
  9. Food and Drug Administration (FDA). FDA Moderization Act of 1997. Public Law 105-115 [cited 2007 Jun 15]; Available from: URL:http: //www.fda.gov/cder/guidance/105-115.htm